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Recent research in identification of brain injury after trauma shows many possible
blood biomarkers that may help identify the fetus and neonate with encephalopathy.
Traumatic brain injury shares many common features with perinatal hypoxic-ischemic
encephalopathy. Trauma has a hypoxic component, and one of the 1st physiologic
consequences of moderate-severe traumatic brain injury is apnea. Trauma and
hypoxia-ischemia initiate an excitotoxic cascade and free radical injury followed by the
inflammatory cascade, producing injury in neurons, glial cells and white matter. Increased
excitatory amino acids, lipid peroxidation products, and alteration in microRNAs
and inflammatory markers are common to both traumatic brain injury and perinatal
encephalopathy. The blood-brain barrier is disrupted in both leading to egress of
substances normally only found in the central nervous system. Brain exosomes may
represent ideal biomarker containers, as RNA and protein transported within the vesicles
are protected from enzymatic degradation. Evaluation of fetal or neonatal brain derived
exosomes that cross the blood-brain barrier and circulate peripherally has been referred
to as the “liquid brain biopsy.” A multiplex of serum biomarkers could improve upon the
current imprecise methods of identifying fetal and neonatal brain injury such as fetal heart
rate abnormalities, meconium, cord gases at delivery, and Apgar scores. Quantitative
biomarker measurements of perinatal brain injury and recovery could lead to operative
delivery only in the presence of significant fetal risk, triage to appropriate therapy after
birth and measure the effectiveness of treatment.
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INTRODUCTION
Worldwide it is estimated that 1.15 million babies develop hypoxic-ischemic encephalopathy (HIE)
every year (Lee et al., 2013). Up to 60% of infants with HIE will die or have severe disabilities by
the age of 2 including mental retardation, epilepsy, and cerebral palsy (Pierrat et al., 2005). The
costs related to HIE exceed $11 billion annually in the U.S. (Lawn et al., 2011). HIE is defined by a
constellation of symptoms in the neonate, and no definitive diagnostic test is available (American
College of Obstetricians Gynecologists, 2014). One of the greatest challenges in perinatal medicine
is assessing the fetus during labor and the neonate shortly after birth for evidence of brain injury.
The presence of meconium, non-reassuring fetal heart rate tracing, Apgar scores, umbilical artery
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blood gases, and physical exam, are tools currently used to
identify brain injury in the fetus and neonate but they all both
separately and collectively lack precision. Amplitude integrated
EEG can detect early changes associated with brain injury
and has been used to determine prognosis and predict long
term outcomes, (Merchant and Azzopardi, 2015) however,
interference from hypothermic environments can reduce the
prediction of HIE prognosis, and amplitude integrated EEG
cannot determine the time of injury (Thoresen et al., 2010).
One of the major challenges that needs to be solved is the
early discrimination of mild-moderate injury from severe injury.
The availability of therapies such as whole-body hypothermia,
which must be instituted within 6 h of birth, make the
rapid identification of a baby with neurologic injury critically
important. How to objectively and quantitatively identify the
fetus and neonate with brain injury may be solved by borrowing
an approach from traumatic brain injury research. Extensive
effort has been applied in the field of traumatic brain injury
to identify acute blood biomarkers as diagnostics to identify
these patients, discriminate severity, monitor treatment efficacy
and as prognostics for recovery and long-term disabilities (Diaz-
Arrastia et al., 2014).
Blood biomarkers are utilized as a diagnostic tool to identify
patients with a possible disease or abnormal condition, e.g.,
elevated glucose levels for the diagnosis of diabetes mellitus
and elevated levels of cardiac troponin for diagnosis of acute
myocardial infarction (Atkinson et al., 2001). Biomarkers
can be used to predict the stage of a disease and its
severity, such as measuring the concentration of prostate-
specific antigen in the blood to detect the level of tumor
growth and metastasis (Mouhieddine et al., 2015). Following
brain injury a destructive cascade of biological events continues
over hours and days that may worsen the patient’s condition
following a primary insult and a secondary reperfusion phase.
The focus of biomarker development in traumatic brain
injury has been on the identification of moderate to severe
injury; (Mondello et al., 2012a) however, the greatest potential
impact of blood biomarkers to change clinical practice in
perinatology is for mild injury since diagnostic and prognostic
challenges presented for mild injuries are more difficult to
identify and monitor (Diaz-Arrastia et al., 2014). There is
no current standard therapy for mild injury and increasingly
late outcomes suggest that mild injury results in identifiable
pathology.
Similar to traumatic brain injury, it is unlikely that a
single biomarker will reflect the full picture of the injured
brain for a multifaceted complex disease such as HIE (Diaz-
Arrastia et al., 2014). Combining biomarkers from multiple
cellular pathways has shown superior sensitivity and specificity
in the identification of traumatic brain injury (Diaz-Arrastia
et al., 2014). Simultaneous measurements of neuronal and glial
biomarkers may complement each other to identify distinct
injury mechanisms and determine the timing of injury. A study
of severe traumatic brain injury found that glial biomarker
elevations are primarily a reflection of focal mass lesions, and
that diffuse injuries primarily result in neuronal biomarker
elevations (Mondello et al., 2012a). Since patients with diffuse
injuries may require different therapies from those with focal
lesions, such a combination of biomarkers may enable us to
select patients for targeted therapies (Saatman et al., 2008;
Diaz-Arrastia et al., 2014). In perinatal medicine this might
allow differentiation of large major vessel stroke from more
diffuse hypoxic-ischemic injuries. The ideal biomarker panel may
include multiple biomarkers produced by different brain cell
types, and currently available multiplex immunoassay platforms
make it possible to measure up to 10 biomarkers with a high
degree of sensitivity from small volumes of plasma (Diaz-Arrastia
et al., 2014). Investigators have proposed developing a point of
care handheld device that can quickly and accurately measure
brain injury biomarkers similar to the handheld dextrometer of
diabetic patients that can measure a glucose level within seconds
(Bressan et al., 2014).
Optimally, the level of the brain injury biomarkers should
correlate with the size, location and severity of the lesion, clinical
outcome and response to treatment (Mouhieddine et al., 2015).
Ideally, serum biomarkers should provide information on the
pathophysiology of injury, improve stratification of patients by
injury severity, assist in the monitoring of secondary insults and
injury progression, monitor response to treatment and predict
functional outcome (Papa et al., 2008). Circulating brain injury
biomarker levels in neonatal HIE could indicate brain injury
and reflect the extent of damage, solving a clinical dilemma in
the discrimination of mild vs. moderate-severe injury (Lv et al.,
2015).
Brain injury biomarker protein discovery can be either
hypothesis driven or discovery driven. In the discovery driven
method samples from normal and brain injured patients are
compared with mass spectrometry to identify differences in
circulating brain proteins. Unlike hypothesis driven research
that identifies potential biomarkers before testing them in cases
and controls, discovery driven research collects a huge amount
of information first then extracts questions and answers from
the data (Guingab-Cagmat et al., 2013). As currently there is
no gold standard for diagnosing mild traumatic brain injury,
not even by conventional assessment through neuroimaging
techniques, (Niogi and Mukherjee, 2010) these approaches have
been applied to identify brain specific markers of injury. During
brain injury, neural proteins or their breakdown products
are released into the extracellular environment reaching the
cerebrospinal fluid (CSF) in relatively high concentration, and
the blood stream via the compromised blood-brain barrier
(Guingab-Cagmat et al., 2013; Figure 1). In premature infants
in particular, the blood brain barrier is particularly fragile,
potentially increasing the likelihood that brain proteins may
reach the circulation after injury (Dammann and Leviton,
1997). Clearance and half-life of the biomarkers contribute
to the final concentration that can be measured in blood
(Guingab-Cagmat et al., 2013). Review of recent research in
traumatic brain injury suggests significant potential for crossover
of traumatic brain injury biomarkers to the brain injured
fetus and neonate. The following biomarkers and classes of
biomarkers may be used as tools to diagnose neonatal brain
injury, follow its treatment efficacy and provide prognostic
information.
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FIGURE 1 | Summary of biomarkers related to perinatal hypoxic-ischemic encephalopathy. ATP, adenosine triphosphate; BDNF, brain derived neurotrophic
factor; C-Tau, cleaved-Tau; G-CSF, granulocyte colony stimulating factor; GFAP, glial fibrillary acidic protein; hsCRP, high sensitivity C-reactive protein; IL, interleukin;
LDH, lactate dehydrogenase; MAP, microtubule-associated protein; MBP, myelin basic protein; miRNA, micro ribonucleic acid; MMP, matrix metalloproteinase; NSE,
neuron specific enolase; PDGFR, platelet derived growth factor receptor; SBDP, spectrin breakdown products; SOD, superoxide dismutase; TNF, tumor necrosis
factor; TSP, thrombospondin; UCH, ubiquitin carboxy-terminal hydrolase; VEGF, vascular endothelial growth factor.
GLIAL FIBRILLARY ACIDIC PROTEIN
(GFAP)
Of the numerous candidate biomarkers for traumatic brain injury
GFAP holds the most promise (Guingab-Cagmat et al., 2013).
One of the main strengths of GFAP as a brain injury biomarker
is that it is only found within the central nervous system (CNS;
Galea et al., 1995). GFAP is a cytoskeletal intermediate filament
protein that forms networks that support astroglial cells and
is found only in the astroglial cytoskeleton (Guingab-Cagmat
et al., 2013). Astrocytes are important to brain injury because
their foot processes comprise part of the blood brain barrier,
and with disruption after injury astrocyte damage results in early
release of GFAP (Vos et al., 2004; Guingab-Cagmat et al., 2013).
GFAP levels peak at 1–2 days following severe brain trauma, and
are normal in patients with other trauma that does not include
traumatic brain injury, an indication of GFAP’s brain specificity
(Schiff et al., 2012). In a study of 81 patients with traumatic
brain injury, serum GFAP levels in the 1st 24 h post-injury were
significantly higher in patients with a focal mass lesion compared
to patients with diffuse injury (Mondello et al., 2011). GFAP may
be an appropriate and sensitive candidate for the diagnosis of
focal brain injury such as contusion or intracerebral hemorrhage
(Yokobori et al., 2013). GFAP may also be important in the
differential diagnosis of various types of stroke, which is clinically
relevant as immediate treatment of stroke depends on whether
the stroke is ischemic or hemorrhagic (Guingab-Cagmat et al.,
2013). In neonates, serum GFAP levels have been shown to be
significantly elevated at the time of birth and during the first week
of life in term and near-term infants with HIE that have abnormal
brain MRI scans at 1 week of life (Ennen et al., 2011; Massaro
et al., 2013; Chalak et al., 2014) and in premature neonates that
develop periventricular white matter injury (Stewart et al., 2013).
In addition, GFAP may provide insights into the pathobiology of
therapeutic hypothermia as significant elevations in GFAP occur
after rewarming from therapeutic cooling for HIE in the neonates
that later have an abnormal MRI, suggesting that the neonates
with severe injury manifest reperfusion injury post-therapuetic
cooling (Schiff et al., 2012). This may offer an opportunity to
discriminate mild from moderate to severe HIE and triage high
risk neonates to evolving adjunctive therapies.
NEURON-SPECIFIC ENOLASE (NSE)
NSE is 1 of 5 isozymes of the glycolytic enzyme enolase found
in central and peripheral neurons and red blood cells and has
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been shown to be elevated following cell injury (Skogseid et al.,
1992). NSE is not normally secreted into extracellular fluids by
intact neurons, but when axons are damaged NSE is upregulated
in an attempt to maintain homeostasis (Yokobori et al., 2013). It
is highly expressed in neuronal cytoplasm and has been shown
to have the sensitivity and specificity to detect neuronal cell
death (Selakovic et al., 2005). Given its location and abundance
NSE should possess relatively high specificity and sensitivity
for axonal injury, and accordingly NSE seems to have excellent
potential as a therapeutic monitor in the neurological intensive
care unit and for the determination of long-term prognosis
(Gradisek et al., 2012). A limitation of NSE is its lack of brain
specificity, being abundant in red blood cells which leads to the
occurrence of false positive results in the setting of hemolysis
(Papa et al., 2008). Increased cerebrospinal fluid (CSF) and
serum levels of NSE have been reported after traumatic brain
injury, and NSE concentrations were associated with severity
of injury, CT scan abnormalities and outcome (Selakovic et al.,
2005; Guingab-Cagmat et al., 2013). NSE has been shown to
provide quantitative measures of brain damage and to improve
the diagnosis and prediction of ischemic stroke, intracerebral
hemorrhage, seizures, comatose patients after cardiopulmonary
resuscitation for cardiac arrest, and traumatic brain injury (Isgro
et al., 2015). There is a positive correlation between NSE levels
and infarct volume after acute ischemic stroke, and serum levels
of NSE in the first few days of ischemic stroke may serve as
a useful marker to predict stroke severity and early functional
outcome (Isgro et al., 2015).
Release patterns of NSE and S100B were investigated in
66 traumatic brain injury patients, and in those with cortical
contusions NSE was highest on the 1st measurement on day
1 after injury, decreasing from this peak over 4 days, while
S100B slowly increased over the 4 day period (Herrmann et al.,
2000). Serum concentrations of NSE and S100Bwere significantly
correlated with contusion volume, but the 1st sample taken
was the most valid indicator of traumatic brain injury severity
(Herrmann et al., 2000). Similarly in 152 pediatric traumatic
brain injury patients higher NSE concentrations were associated
with worse outcome, and initial and peak NSE concentrations
correlated with Glasgow Outcome Scale score at all time points
investigated, particularly in children < 4 years of age (Berger
et al., 2007).
S100B
S100B is the principal low affinity calcium-binding protein in
astrocytes and is considered a marker of astrocyte injury and
death (Papa et al., 2008). Although S100B is glial specific and
expressed primarily by astrocytes and Schwann cells, it is also
found in several non-nervous system cells such as adipocytes,
chondrocytes, skin, glioblastoma, and melanoma cells (Zimmer
et al., 1995). S100B has a serum half-life of only 2 h, (Guingab-
Cagmat et al., 2013) but is stable in blood and not affected by
hemolysis (Lv et al., 2015). Since S100B is produced outside
the CNS, general trauma without brain injury can increase its
levels (Rothoerl and Woertgen, 2001). S100B spikes up after
hemorrhagic shock and correlates with shock severity which
decreases it’s value as a single biomarker for traumatic brain
injury (Guingab-Cagmat et al., 2013). It may be possible to use
S100B as a biomarker of brain injury if measured immediately
after injury; however, most mild brain injury patients are not
evaluated at the time the injury occurs (Guingab-Cagmat et al.,
2013).
S100B levels in blood at 24 h post-traumatic brain injury
provides an early and sensitive biomarker for the prediction
of brain damage which may be useful in defining early risk
patterns (Egea-Guerrero et al., 2013). Elevated serum levels of
S100B correlate with MRI abnormality and neuropsychological
examination after mild traumatic brain injury (Ingebrigtsen
et al., 1999). In 265 patients with traumatic brain injury S100B
levels added substantial information regarding patient outcome
in excess of that provided by age, Glasgow Coma Scale, pupil
reaction and CT scan, and elevated S100B levels were best
correlated to CT-visible intracranial pathology (Thelin et al.,
2013). It has been estimated that adding the measurement of
S100B to clinical decision tools for mild traumatic brain injury
patients could potentially reduce the number of CT scans by 30%
(Biberthaler et al., 2006). Furthermore, S100B below a threshold
level may also safely eliminate the need to obtain a CT scan in
patients with mild traumatic brain injury (Unden et al., 2013).
A significant correlation has been found between the volume of
contusion visible on CT scan and serum S100B concentration
(Raabe et al., 1998).
Cord blood concentration of S100B > 2.20 µg/L has a
sensitivity of 87% and specificity of 88% in predictingmoderate to
severe HIE (Qian et al., 2009). Serum concentrations of S100B 2 h
after birth of 8.5 µg/L predict the occurrence of severe neonatal
HIE (Nagdyman et al., 2001). Salivary S100B levels may also
be able to predict neonatal neurologic abnormalities related to
asphyxia (Gazzolo et al., 2015). In patients with severe traumatic
brain injury S100B appears to be a more accurate biomarker for
predicting intracranial hypertension thanNSE, particularly in the
early post-injury phase (Yokobori et al., 2013). In neonates with
HIE treated with hypothermia or normothermia, both NSE and
S100B levels were highly elevated following asphyxia, however,
serum S100B levels were lower in the hypothermia group and
strongly correlated with the neurodevelopmental outcome (Roka
et al., 2012).
UBIQUITIN CARBOXY-TERMINAL
HYDROLASE L1 PROTEIN (UCHL1)
UCHL1, also known as neuronal-specific protein gene product
9.5, is a cysteine protease that is predominately expressed
in neurons, but is also expressed in small amounts in
neuroendocrine cells (Guingab-Cagmat et al., 2013). This small
(25 kDa) enzyme comprises about 2% of the total soluble protein
in the brain and hydrolyzes the C-terminal bond of ubiquitin or
unfolded polypeptides (Setsuie and Wada, 2007). Because of its
high and specific expression in brain tissue, increased levels of
UCHL1 have been suggested as a marker of CNS injury such as
acute cerebral ischemic disease and early stage severe traumatic
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brain injury (Lv et al., 2015). SerumUCHL1 is a useful biomarker
of severe traumatic brain injury both in the acute phase and in
the 1st week after injury (Mondello et al., 2012b). In 251 patients
with suspected mild to moderate traumatic brain injury UCHL1
outperformed GFAP and S100B in reducing CT scan use without
sacrificing sensitivity (Welch et al., 2016). Of the 3 biomarkers,
UCHL1 had the best test performance to differentiate between
subjects with normal vs. abnormal CT scans (Welch et al., 2016).
When obtained within 6 h of injury UCHL1 in combination with
GFAP was very sensitive for a positive head CT, and was thought
to provide the objective evidence clinicians desire when trying to
reduce the use of CT scans in patients with mild traumatic brain
injury (Welch et al., 2016). Serum UCHL1 levels were higher
in patients with diffuse injury, in contrast to GFAP levels which
were higher in patients with focal mass lesions (Mondello et al.,
2011). High levels of UCHL1 have been found in the umbilical
cord blood of neonates with HIE associated cortical injury and
subsequent movement and cognitive disorders (Massaro et al.,
2013; Douglas-Escobar et al., 2014).
CLEAVED TAU (C-TAU)
Tau is an intracellular, microtubule associated protein that
is highly enriched in axons which stably assembles axonal
microtubule bundles and participates in anterograde axoplasmic
transport (Yokobori et al., 2013). Tau is preferentially localized
in the axon, and Tau lesions are related to axonal disruption
(Higuchi et al., 2002). Under normal conditions axonal Tau
is below the level of detection, however, after axonal injury
activated calpain depolymerizes microtubules in both perikarya
and neurites to form filamentous Tau inclusions which are a
pathologic hallmark of axonal injury (Yokobori et al., 2013).
A cleaved form of Tau has been investigated as a potential
biomarker of CNS injury (Papa et al., 2008). C-Tau levels in
the CSF are significantly elevated after traumatic brain injury,
and these levels correlate with clinical outcome (Zemlan et al.,
2002). Although levels of C-Tau were also elevated in plasma
from patients with severe traumatic brain injury, there was
no correlation between plasma levels and clinical outcome
(Chatfield et al., 2002). Serum Tau protein concentrations are
significantly increased in bilirubin encephalopathy of newborns,
and there is significant correlation between Tau levels and the
severity of brain injury (Okumus et al., 2008).
MICROTUBULE-ASSOCIATED PROTEIN 2
(MAP2)
MAP2 is primarily expressed in the nervous system and is one
of the most abundant proteins in the brain (Yokobori et al.,
2013). MAP2 is generally dendrite-specific and potentially a good
candidate biomarker for dendritic injury (Kobeissy et al., 2008).
A study of 16 patients with severe traumatic brain injury found
that serum MAP2 concentrations correlated with neurologic
outcome at 6 months after injury (Mondello et al., 2012c).
Perinatal asphyxia has been shown to affect the distribution of
MAP2 in the brainstem of children (Covenas et al., 2014).
MYELIN BASIC PROTEIN (MBP)
MBP is the major component of the myelin sheath, and has a
crucial role in the maintenance of myelin structure and function
(Barbarese et al., 1988). It is one of the most abundant proteins
in white matter, representing 30% of the protein content of
myelin (Yokobori et al., 2013). Under normal conditions only
a small amount is released into the blood stream, but in white
matter brain injury the concentration of MBP in blood and
CSF increases rapidly reflecting the severity of myelin damage
which allows MBP to be used as a specific biomarker of white
matter lesions or nerve fiber demyelination (Lv et al., 2015). MBP
diminishes significantly in the contused rat cortex as early as 2
h after traumatic brain injury reaching its lowest level at 48 h
(Ottens et al., 2008). Serum and CSF MBP has been studied as
a biomarker for traumatic brain injury and for determination
of outcome (Yokobori et al., 2013). Levels of serum MBP in
neonates with moderate to severe HIE was significantly higher
than those with mild HIE and no injury (Lv et al., 2015).
SPECTRIN BREAKDOWN PRODUCTS
(SBDP)
Alpha-II-spectrin is the main structural component of the
cortical membrane cytoskeleton and is particularly abundant in
axons and presynaptic terminals (Riederer et al., 1986). Alpha-
II-spectrin is a major substrate for both calpain and caspase-
3 cysteine proteases, and is cleaved into breakdown products
that may serve as biomarkers of brain injury (Guingab-Cagmat
et al., 2013). A signature of caspase-3 and calpain activation is
cleavage of several common proteins such as cytoskeletal alpha-
II-spectrin (Ringger et al., 2004). Since calpain and caspase-3 are
major executioners of necrotic and apoptotic cell death during
ischemia and trauma, SBDP may provide crucial information
not only on the severity of brain injury, but also on the
underlying pathophysiological mechanisms associated with cell
death (Guingab-Cagmat et al., 2013). Calpain and caspase-3
mediated SBDP levels in CSF are significantly increased in
patients after traumatic brain injury (Pineda et al., 2007). Average
SBDP values measured early after injury correlate with severity
of injury, CT scan findings and outcome at 6 months post-
injury (Pineda et al., 2007). This is consistent with activation of a
continuum of cell death mechanisms over different time courses
following severe traumatic brain injury, and shows that SBDP are
potentially useful biomarkers of severe traumatic brain injury and
may provide information about the timing of injury (Papa et al.,
2008).
BRAIN-DERIVED NEUROTROPHIC
FACTOR (BDNF)
BDNF is a neurotrophin secreted by CNS neurons and astrocytes
that is involved in neuronal survival and synaptic plasticity.
BDNF promotes the growth, differentiation, regeneration and
repair of neurons (Lv et al., 2015). Proinflammtory cytokines
enhance neurotrophic signaling via expression of BDNF (Werner
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and Stevens, 2015). Decreased levels of serum BDNF have
been associated with higher clinical severity of traumatic brain
injury and with decreased 6-month functional outcome scores
(Korley et al., 2016). After traumatic brain injury serum BDNF is
acutely decreased correlating with injury severity, and therapies
that increase brain BDNF expression, such as environmental
enrichment, show promise for cognitive recovery (Failla et al.,
2016). In 113 traumatic brain injury patients with serum BDNF
levels measured 0–6 days (acute) and 6–12 months (chronic)
post-injury, serum BDNF levels were reduced after traumatic
brain injury at all time points (Failla et al., 2016). Acute serum
BDNF may be a viable predictive biomarker for mood and
cognitive complications within the 1st year after traumatic brain
injury, and BDNF may provide a treatment window in the
acute phase that affects long term recovery (Failla et al., 2016).
Chronic serum BDNF may be reflective of injury severity and
serve as a potential biomarker for tracking treatment response
and effectiveness in real-time (Failla et al., 2016). If serum BDNF
levels are persistently elevated in neonates with HIE this suggests
severe brain injury and a poor prognosis (Imam et al., 2009).
ACTIVIN A
Activin A is a trophic factor that regulates neuron proliferation
and is a member of the transforming growth factor β superfamily
(Lv et al., 2015). Activin A has been shown to protect from
hypoxic-ischemic damage in cell culture and animal models
(Mukerji et al., 2007). Hydrogen peroxide treatment increased
activin mRNA twofold in surviving cortical neurons, and
inhibition of activin with neutralizing antibodies caused neuronal
death (Mukerji et al., 2007). After transient focal cerebral
ischemia in adult mice, activin mRNA increased at 1 and 4 h
ipsilateral to the infarct but returned to control values at 24 h
after reperfusion (Mukerji et al., 2007). Activin was also increased
after 2 h of 11% hypoxia (Mukerji et al., 2007). Activin mRNA
increased at 1 h, but not 4 or 24 h after hypoxia, similar to the time
course of erythropoietin and vascular endothelial growth factor
induction (Mukerji et al., 2007). This shows that activin is an
early-regulated gene response to transient ischemia and hypoxia
(Mukerji et al., 2007). Because activin responds to oxidative
challenge protecting neurons, it may have a role as a potential
therapy in stroke injury (Mukerji et al., 2007). In full term
neonates with moderate to severe HIE, activin A is significantly
elevated in CSF, and it may be a reliable early indicator for the
identification of HIE (Imam et al., 2009).
MATRIX METALLOPROTEINASE-9 (MMP-9)
MMP-9 is involved in the breakdown of the blood-brain barrier
by degrading brain vasculature basementmembrane components
(Lv et al., 2015). Under the effect of inflammatory mediators
and oxygen free radicals MMP-9 is activated, and the basement
membrane of the blood-brain barrier is damaged, increasing
permeability and causing secondary vascular source cerebral
edema, which is part of the pathophysiology of HIE (Lv et al.,
2015). Serum MMP-9 is significantly elevated in neonates with
HIE, and its elevation is related to the time of onset (Liu et al.,
2009). A sustained increase of serum MMP-9 concentrations
in neonates with HIE indicates worsening blood-brain barrier
damage leading to brain damage and edema (Lv et al., 2015).
VASCULAR ENDOTHELIAL GROWTH
FACTOR (VEGF)
VEGF is an angiogenic factor secreted by astrocytes and
microglia that is overexpressed in hypoxia-ischemia and protects
neurons and glial cells by promoting the proliferation and
angiogenesis of vascular endothelial cells (Lv et al., 2015). Brain
VEGF mRNA expression increases and reaches a sustained peak
at 12 h of life for a duration of 14 days or longer in animal
models of hypoxia-ischemia (Liang and Wang, 2005). Plasma
concentrations of VEGF increase with increased severity of
neonatal HIE (Lv et al., 2015).
PLATELET DERIVED GROWTH FACTOR
RECEPTOR β (PDGFRβ)
The integrity of the blood-brain barrier is essential for proper
neuronal functioning, and pericytes are crucial for maintaining
blood-brain barrier integrity. Brain capillary pericyte dysfunction
results in blood-brain barrier breakdown and contributes to
neurological injury (Sagare et al., 2015). PDGFRβ is expressed
in the brain by vascular mural cells, brain capillary pericytes
and arterial vascular smooth muscle cells, and is a marker
for blood-brain barrier disruption (Sagare et al., 2015). In
cultures of human brain pericytes exposed to hypoxia PDGFRβ
is a biomarker of pericyte injury (Sagare et al., 2015).
Elevated PDGFRβ in biofluids in patients with neurodegenerative
disorders likely reflects ongoing pericyte injury and supports its
potential to be developed and validated as a biomarker of brain
pericyte injury and blood-brain barrier dysfunction (Sagare et al.,
2015). Inflammation, induced either by trauma or hypoxia, can
induce blood-brain barrier disruption by altering tight junction
function leading to paracellular leakage and affecting vesicular
processes leading to transcytotic leakage of potential biomarkers
(Banks et al., 2015). To date PDGFRβ has not been studied in
neonatal HIE.
THROMBOSPONDIN-1 (TSP-1)
Angiogenesis is a fundamental endogenous process for brain
development and repair. TSP-1 is the 1st identified endogenous
angiogenesis inhibitor, and its expression is upregulated after
intracerebral hemorrhage (Dong et al., 2015). TSP-1 may
be released into the CSF from damaged brain tissue with
recirculation into the peripheral blood (Dong et al., 2015).
In 110 patients with intracranial hemorrhage compared to
age and gender matched healthy controls increased plasma
TSP-1 concentrations following intracranial hemorrhage were
independently associated with injury severity and short and
long term clinical outcomes (Dong et al., 2015). TSP-1
may be a useful complementary tool to acutely assess the
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severity of injury and predict poor clinical outcomes following
acute intracranial hemorrhage which may make it an ideal
biomarker to determine prognosis in premature neonates with
intraventricular hemorrhage. TSP-1 has not been studied in
neonates with HIE.
INFLAMMATION RELATED MARKERS
Because neuroinflammation is such a prominent feature of
traumatic brain injury, cytokines have been investigated as
potential biomarkers. Cytokines play both harmful and curative
roles in traumatic brain injury, readily cross the blood-brain
barrier and may relay important information on the severity
and prognosis of injury (Banks et al., 2016). High sensitivity
C-reactive protein is a sensitive marker of inflammation and
tissue injury whose concentration increases rapidly in brain
tissue following hypoxia-ischemia. In 74 neonates with HIE
high sensitivity C-reactive protein, interleukin-6 and tumor
necrosis factor-α (TNF-α) were significantly increased, and high
levels correlated with a poor prognosis (Shang et al., 2014).
High sensitivity C-reactive protein reaches a peak at day 3
of life then begins to decrease; if the serum concentration
fails to decrease the prognosis is poor (Tian and Yan,
2012).
Interleukin-1β (IL-1β) promotes brain damage through the
release of free radicals, stimulating inflammatory reactions,
and enhancing the toxicity of excitatory amino acids (Lv
et al., 2015). In neonates with HIE elevated serum IL-1β
levels are associated with neurological abnormalities at 6–
12 months (Liu and Feng, 2010). In 16 deceased full term
asphyxiated infants there was increased expression of IL-1β
in the hippocampus in those with seizures, and all cases
with seizures displayed alteration in the blood-brain barrier
as assessed by immunohistochemistry for albumin (Schiering
et al., 2014). The authors speculated that seizure development
may lead to secondary brain damage, and that IL-1β may aid
in the development of therapeutic targets for neonatal seizures
(Schiering et al., 2014).
IL-6 is produced by glial cells and has a protective effect
on the CNS by inhibiting the synthesis of TNF-α and IL-1
and promoting nerve growth factor secretion. However, high
concentrations of IL-6 can induce inflammation and increase
vascular permeability leading to cerebral edema (Lv et al., 2015).
When the cord blood of 50 neonates with HIE was compared
to 113 controls, IL-6 levels were significantly elevated, aiding the
diagnosis of brain injury, andwere related to prognosis (Wu et al.,
2012).
IL-8 is a neutrophil chemotaxis factor that recruits neutrophils
to injured areas, and through enhanced IL-1β and TNF-α
neurotoxicity increases brain injury (Lv et al., 2015). IL-8
increases in the acute phase of injury in neonates with HIE, and
the more severe the injury the higher the IL-8 levels (Lv et al.,
2015). In a study of 13 neonates with HIE and epilepsy, most
inflammatory factors in the serum were decreased after 8–72 h,
however, serum IL-8 levels remained high indicating that IL-8
might be an early biomarker for the diagnosis of neonatal HIE
with epilepsy (Youn et al., 2012).
IL-10 plays a protective role in brain tissue by inhibiting the
secretion of IL-1β, IL-8, and TNF-α, inhibiting the production
of chemokines, decreasing leukocyte aggregation, and reducing
inflammatory responses in the brain (Lv et al., 2015). IL-10 levels
are significantly elevated in the acute phase of injury in neonates
with HIE (Wang et al., 2003).
IL-18 is an anti-inflammatory factor that stimulates the
expression of IL-1β and IL-8, and can both protect brain tissue
and aggravate brain damage (Felderhoff-Mueser et al., 2005).
Serum levels of IL-18 are elevated in neonates with HIE, and
levels correlate with the severity of brain damage (Guo et al.,
2014).
TUMOR NECROSIS FACTOR ALPHA
(TNF-α)
Systemic inflammation leads to increased CNS inflammation
and injury through direct transport of inflammatory agents or
inflammatory cells across the blood-brain barrier, and it has
been proposed that infection-induced upregulation of TNF-α can
produce or worsen brain injury (Leviton, 1993). This hypothesis
is supported by various studies showing that pro-inflammatory
cytokines such as TNF-α produced by the placenta can cross the
blood-brain barrier (Jin et al., 2015).
Intra-amniotic infections lead to preterm delivery which
increases the risk of neurologic morbidity in preterm neonates.
Elevated amniotic fluid levels of the inflammatory cytokines
TNF-α, IL-1β, and IL-6 are linked with white matter injury in
preterm neonates, (Yoon et al., 1997) and elevated cord blood
levels of these cytokines correlate with neonatal cerebral lesions
on MRI (Duggan et al., 2001). In preterm infants, an elevated
inflammatory response during the perinatal period correlates
with long term morbidities including cerebral palsy, necrotizing
enterocolitis, bronchopulmonary dysplasia, and chronic lung
disease (Jin et al., 2015). Elevated inflammatory cytokines
measured in neonatal blood correlate with periventricular white
matter injury, ventriculomegaly and severe germinal matrix
hemorrhage assessed by ultrasound (Nelson et al., 2003). At this
point extensive literature strongly supports the bioplausibility
of all of these inflammatory cytokines as biomarkers of
neonatal HIE.
GRANULOCYTE COLONY STIMULATING
FACTOR (G-CSF)
G-CSF mobilizes stem cells and is currently used to promote
the production of neutrophils in chemotherapy patients that
develop neutropenia. G-CSF has neuroprotective properties
after peripheral administration and is protective against carbon
monoxide toxicity and ischemia (Banks et al., 2016). Serum levels
of G-CSF correlate with severity of stroke (Yu et al., 2012) and
are diagnostic for gliomas (Yildiz et al., 2011). G-CSF was the
only cytokine of 23 measured whose serum levels were elevated
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after traumatic brain injury in a murine model (Dohi et al.,
2014). High levels of G-CSF are associated with better functional
outcome and reduced lesion volume in intracranial hemorrhage
(Sobrino et al., 2009). G-CSF is elevated 2 h after controlled
cortical injury, but not at later time points in mice, which may
make it useful in determining the timing of injury (Dohi et al.,
2014). Plasma G-CSF levels correlate with neuroinflammation in
the same mouse models (Dohi et al., 2014) and in human studies
where they correlate with time since injury and total severity of
injury (Banks et al., 2016). In a neonatal rat HIE model treatment
with G-CSF has been shown to attenuate long term brain damage
(Fathali et al., 2010).
OXIDATIVE STRESS RELATED MARKERS
Free radicals cause lipid peroxidation of cell membranes, and
the antioxidant enzyme superoxide dismutase and the lipid
peroxidation product malondialdehyde reflect the extent of
oxidative damage to cells (Lv et al., 2015). Excess free radicals
consume a large amount of superoxide dismutase and produce
a large amount of malondialdehyde, which may allow these
compounds to be used for the early prediction of neonatal HIE,
but they are not brain specific (Qin et al., 2005).
METABOLISM RELATED MARKERS
Since perinatal hypoxia-ischemia leads to brain injury through an
increase in anaerobic metabolism, clinical testing of metabolites
may help identify the neonate with HIE and follow their recovery
(Lv et al., 2015). Hypoxia leads to an increase in anaerobic
glycolysis, decreased ATP production, and accumulation of lactic
acid. Lactate dehydrogenase exists in neuronal cytoplasm and
mitochondria, and its role is to catalyze the oxidation of lactate
to pyruvate. At the onset of neonatal HIE lactate dehydrogenase
activity and lactate production are increased, and a combination
of lactate dehydrogenase and NSE may be used to identify brain
injury (Lv et al., 2015). Detection of lactate dehydrogenase with
other metabolites may have an important role in neonatal HIE
diagnosis and prognostic evaluation (Lv et al., 2015).
Extracellular glutamate primarily mediates excitotoxicity and
is involved in the pathophysiological processes of brain ischemia
(Lv et al., 2015). During HIE ATP synthesis decreases, glutamate
transport is inhibited and glutamate accumulates in the neuronal
synaptic cleft subsequently leading to neuronal death (Lv et al.,
2015). Because glutamate is brain specific, it can be a sensitive
biomarker for brain injury, and if monitored early may aid in the
early diagnosis of HIE in the neonate and could be a marker of
therapeutic efficacy as ancillary therapies are developed for HIE
(Lv et al., 2015).
MICRORNA (miRNA)
MicroRNA (miRNA) are being investigated as promising
serum biomarkers for neurotrauma. miRNA may be stable in
the circulation which supports their potential use as disease
biomarkers (Egea et al., 2012). miRNAs are endogenously
expressed ∼22 nucleotide long noncoding RNAs that control a
wide spectrum of cellular function, and bind to target regions
of certain genes to control their expression by either repression
or activation of mRNA translation/transcription (Chen et al.,
2015). miRNAs play important roles in developmental and
functional aspects of the CNS and in many neurological diseases,
which potentially make them important candidates for brain
injury diagnosis (Chen et al., 2015). Emerging data suggest that
exosomal miRNA may provide potential biomarkers in acute
ischemic stroke (Chen et al., 2015). Studies of endothelial cell
cultures and in vivo rat focal ischemia models have shown
significant reductions in serum miR-126 detected at 3 h after
permanent ischemia but not transient ischemia, which suggests
that changes in serum miR-126 may be able to distinguish
severe permanent ischemia from milder injury after transient
ischemia (Chen et al., 2015). miR-126 was selected as the
initial candidate biomarker of neurovascular damage in stroke
because it is specifically and highly expressed in endothelial
cells and is known to be involved in the regulation of vascular
integrity, endothelial function, and angiogenesis (Chen et al.,
2015). miRNAs have been shown to be altered in plasma before
the first spontaneous seizure and have been proposed as putative
biomarkers of epileptogenesis (Roncon et al., 2015). Recently
miRNAs have been found to be involved in the pathophysiology
of HIE, including the regulation of excitatory amino acid
toxicity, oxidative stress, inflammatory reactions and apoptosis
(Lv et al., 2015). Plasma miRNA profiles compared between
severe traumatic brain injury patients and healthy volunteers
found that decreases in the levels of miR-16 and miR-92a
and increased levels of miR-765 were good markers of severe
traumatic brain injury at 25–48 h after injury (Redell et al.,
2010). Specific miRNAs seem to be good candidate biomarkers
for distinguishing focal and diffuse brain injury or for accurate
determination of raised intracranial pressure (Yokobori et al.,
2013). Animal models of neonatal HIE have shown specific
miRNA changes following injury using microarray (Weiss et al.,
2012). Expression of miR-21 is found in astrocytes. A study
of 49 cases of neonatal HIE showed that serum miR-21 was
significantly increased and may be a marker for the early
diagnosis of neonatal HIE (Chen and Yang, 2012).
EXOSOMES
A potentially transformative finding in traumatic brain injury
research has been the identification of exosomes, which are nano-
sized extracellular vesicles that have key roles in cell signaling and
undergo membrane fusion so that they readily cross the blood-
brain barrier. Exosomes contain proteins, miRNA and other
nucleic acids, and are believed to play a major role in disposal of
cellular waste (Werner and Stevens, 2015). Exosomes may serve
as vehicles for targeted delivery of repair-inducing molecules and
possibly as novel biomarkers (Werner and Stevens, 2015). They
have been implicated in an array of signaling processes involving
astrocytes, oligodendrocytes, microglia, neurons, and neural
stem cells (Rajendran et al., 2014). Increased levels of exosomes
have been found after traumatic brain injury in humans (Patz
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et al., 2013). Injured neurons release the microtubule-associated
protein Tau which is then carried by exosomes (Rajendran et al.,
2014). Exosomes may represent ideal biomarker containers, as
RNA and protein transported within the vesicles are protected
from enzymatic degradation, and there is considerable interest
in developing assays to evaluate blood-borne brain-derived
exosomes, often referred to as the “liquid brain biopsy” (Werner
and Stevens, 2015).
CONCLUSION
Blood biomarkers discovered in traumatic brain injury could
significantly improve the management of neonates with HIE,
particularly those with mild and moderate injury, by providing
more accurate early diagnosis and prognosis, and for monitoring
therapies in the acute care setting (Papa et al., 2008). Biomarkers
could help determine severity and mechanism of injury and
quantitatively measure injury progression which would provide
major opportunities for clinical research (Papa et al., 2008).
Serum based combined multi-marker analysis reflecting
glial and neuronal cell damage should be considered for
understanding more precise pathophysiological mechanisms of
brain injury. Glial injury can be assessed by GFAP in the blood
and axonal injury by C-Tau and spectrin protein breakdown
products (Guingab-Cagmat et al., 2013). The serum levels of glial
and neuronal biomarkers (S100B, GFAP, UCHL1) at the time of
admission after brain injury have been shown to correlate with
clinical outcome and are sensitive and specific in determining the
severity of injury (Lee et al., 2015). With UCHL1 levels increasing
in diffuse injury and GFAP levels increasing in focal injury,
a glial:neuronal ratio has been proposed as a novel indicator
to differentiate focal and diffuse injury, and has been found
to be more accurate when measured at < 12 h after injury
(Mondello et al., 2012a). Several potential epilepsy biomarkers
have been proposed in recent years including blood biomarkers
of inflammation, blood-brain barrier damage and brain injury.
Given the complexity of epilepsy it is unlikely that a single
biomarker is sufficient for predicting epileptogenesis, but a
combinatorial approach may be able to identify appropriate
biomarkers at different stages of the evolution of the disease
(Loscher et al., 2013).
The pathology of perinatal HIE is very heterogeneous and
one “magic” biomarker may not be the solution, but a panel
of biomarkers may prove to be most useful in distinguishing
the different pathologic-anatomic processes that comprise the
injury (Papa et al., 2008). The brain consists of many elements,
and depending on the mechanism and severity of injury, various
damage patterns may be reflected by different combinations
of biomarkers (Lee et al., 2015). Biomarkers will probably
supplement existing tools, such as the Glascow Coma Scale and
neuroimaging, for the initial classification of brain injury in the
near future (Papa et al., 2008). As the hypoxic injury pattern
on MRI is not diagnostic for 7–14 days, a blood biomarker
that could fill the clinical gap for predicting current and
worsening neurological status or long-term disability and would
have great clinical utility. With the combinations of different
pathophysiology related to each biomarker, a multi-biomarker
analysis would seem to be the most effective way to assess brain
injury and would likely increase diagnostic accuracy (Yokobori
et al., 2013).
Blood biomarkers offer an objective and quantitative way to
identify and follow a neonate with brain injury. They could
be used to triage neonates to the current standard of 72 h
of hypothermia as well as investigational therapies such as
erythropoietin, xenon gas, melatonin and various forms of
stem cell treatment. Blood biomarkers could possibly provide
information about the extent of injury in the acute phase before
ultrasound or MRI can identify abnormalities and determine
the timing of injury as well. Blood biomarkers measured
noninvasively using near-infrared spectroscopy (Torricelli et al.,
2014) or optoacoustic techniques (Petrov et al., 2012a,b) may also
allow quantitative monitoring of the fetal brain for injury during
the intrapartum period through a dilated cervix with ruptured
membranes via a probe attached to the fetal head similar to the
currently used fetal scalp clip for measuring heart rate. Rather
than imprecise measures of fetal and neonatal brain injury such
as fetal heart rate abnormalities, meconium, cord gas at delivery,
and Apgar scores, a multiplex combining glial and neuronal
biomarkers could provide objective evidence of the extent and
pattern of injury which would lead to improved identification of
the brain injured fetus or neonate, operative delivery only in the
presence of a significant risk of HIE, triage to appropriate therapy
after birth and serve as an objective measure of the effectiveness
of treatment for the brain injured baby.
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